Insider Sell: Teva Pharmaceutical Industries
MT Newswires · 2d ago
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
Benzinga · 4d ago
Teva wins U.K. approval for Lucentis biosimilar
Teva Pharmaceutical (NYSE:TEVA) announced on Tuesday that the U.K. Medicines & Healthcare Regulatory Agency (MHRA) licensed Ongavia, a biosimilar to wet AMD medication Lucentis marketed by the Genentech unit of
Seekingalpha · 4d ago
Teva raised to Neutral at BofA citing a near-term opioid deal
Bank of America upgraded the Israeli drugmaker Teva Pharmaceutical (NYSE:TEVA) to Neutral from Underperform on Tuesday, citing a shift in the attention to the company’s product portfolio following a potential
Seekingalpha · 4d ago
Teva Pharmaceutical touts real-world data on ProAir Digihaler for asthma
New study data suggests that digital inhalers such as Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir Digihaler can help lower short-acting beta agonist (OTCPK:SABA) overuse and assist doctors in making clinical decisions. Results
Seekingalpha · 4d ago
Sector Update: Health Care
MT Newswires · 4d ago
Teva Highlights UK Medicines & Healthcare Regulatory Agency Decision To Grant License For Ongavia
MHRA today granted a licence for Ongavia®▼ (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic
Benzinga · 4d ago
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the firs...
Business Wire · 4d ago
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J., May 17, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM. Th...
Business Wire · 4d ago
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
TEL AVIV, Israel & PARSIPPANY, N.J., May 17, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study findings based on newly established clinical thresholds on short-acting beta agonist...
Business Wire · 4d ago
BofA Securities Upgrades Teva Pharmaceutical Industries to Neutral From Underperform; Price Target is $9
MT Newswires · 5d ago
Pfizer COVID-19 antiviral priced at under $25 per course by generic drugmakers
A group of generic drug manufacturers agreed to make versions of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid at under US$25 per treatment course, The Clinton Health Access Initiative (CHAI) announced on
Seekingalpha · 05/12 16:23
4 Analysts Have This to Say About Teva Pharmaceutical Indus
Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will ...
Benzinga · 05/12 15:07
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J., May 12, 2022--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new findings will be presented at the 2022 American Thoracic Society (ATS) 202...
Business Wire · 05/12 12:00
Teva, Allergan Willing to Pay $5 Billion for Opioid Accord
Bloomberg · 05/10 19:10
BRIEF-Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration Of ESG Into Business, Robust Targets And Strengthened ESG Governance Structure · 05/10 12:10
Walgreens, CVS, Walmart begin $878 million opioid trial in Ohio · 05/10 10:00
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Zacks · 05/04 15:07
Teva downgraded at Piper Sandler on bleak M&A prospects
The ADRs of Teva Pharmaceutical (NYSE:TEVA) have lost ~2% in pre-market Wednesday after Piper Sandler lowered its recommendation on the Israeli pharma company to Underweight from Neutral. The analyst David Amsellem highlights
Seekingalpha · 05/04 12:18
--Piper Sandler Downgrades Teva Pharmaceutical Industries to Underweight From Neutral, Adjusts Price Target to $7 From $11
MT Newswires · 05/04 06:19
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.